Stockscreener 앱 받기
79.67
0.71%
0.56
시간 외 거래:
79.67
전일 마감가:
$79.11
열려 있는:
$79.88
하루 거래량:
1.40M
Relative Volume:
0.60
시가총액:
$12.90B
수익:
$705.14M
순이익/손실:
$-453.90M
주가수익비율:
-26.21
EPS:
-3.04
순현금흐름:
$-551.29M
1주 성능:
-0.33%
1개월 성능:
-2.02%
6개월 성능:
+82.77%
1년 성능:
+129.66%
1일 변동 폭
$78.02
$80.21
1주일 범위
$78.02
$80.21
52주 변동 폭
$23.95
$83.61
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
명칭
Ionis Pharmaceuticals Inc
전화
(760) 931-9200
주소
2855 GAZELLE COURT, CARLSBAD, CA
IONS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
79.67 | 12.81B | 705.14M | -453.90M | -551.29M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-08 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2025-09-26 | 업그레이드 | Goldman | Sell → Neutral |
| 2025-09-03 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-31 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-01 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2025-04-07 | 개시 | H.C. Wainwright | Buy |
| 2025-03-31 | 개시 | Redburn Atlantic | Neutral |
| 2024-08-02 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | 재개 | Jefferies | Buy |
| 2024-06-14 | 업그레이드 | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-10-23 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-09-29 | 개시 | Raymond James | Strong Buy |
| 2023-07-31 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-06-07 | 재개 | Piper Sandler | Overweight |
| 2023-05-04 | 업그레이드 | Citigroup | Sell → Neutral |
| 2023-03-21 | 개시 | Bernstein | Underperform |
| 2022-12-21 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | 재개 | Morgan Stanley | Overweight |
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
| 2022-03-31 | 재개 | Piper Sandler | Overweight |
| 2022-03-01 | 개시 | Citigroup | Sell |
| 2022-03-01 | 개시 | Guggenheim | Buy |
| 2022-02-01 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2021-12-14 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | 업그레이드 | UBS | Sell → Neutral |
| 2021-03-01 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2020-12-16 | 개시 | UBS | Sell |
| 2020-12-15 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2020-09-14 | 재개 | JP Morgan | Neutral |
| 2020-09-02 | 개시 | The Benchmark Company | Hold |
| 2020-06-01 | 재개 | Oppenheimer | Outperform |
| 2020-05-13 | 개시 | RBC Capital Mkts | Outperform |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2019-12-13 | 개시 | Oppenheimer | Outperform |
| 2019-11-13 | 개시 | BofA/Merrill | Buy |
| 2019-11-07 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | 재확인 | Stifel | Hold |
| 2018-08-07 | 재확인 | Stifel | Hold |
| 2018-05-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2017-10-06 | 재개 | Goldman | Sell |
| 2017-08-17 | 개시 | Evercore ISI | Outperform |
| 2017-08-09 | 재확인 | Stifel | Hold |
| 2017-03-10 | 다운그레이드 | Goldman | Neutral → Sell |
| 2016-12-28 | 재확인 | BMO Capital Markets | Outperform |
| 2016-12-27 | 재확인 | Leerink Partners | Mkt Perform |
모두보기
Ionis Pharmaceuticals Inc 주식(IONS)의 최신 뉴스
Stock Traders Buy High Volume of Ionis Pharmaceuticals Call Options (NASDAQ:IONS) - MarketBeat
Death Cross: Can Ionis Pharmaceuticals Inc stock continue upward trendMarket Movers & Reliable Breakout Forecasts - moha.gov.vn
Revenues Not Telling The Story For Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - 富途牛牛
162,800 Shares in Ionis Pharmaceuticals, Inc. $IONS Bought by Capricorn Fund Managers Ltd - MarketBeat
Cns Specific Antisense Oligonucleotide MarketForecast - openPR.com
Ionis Pharmaceuticals Earnings Notes - Trefis
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Ionis Pharmaceuticals Sees Rapid Rise On RNA Drug Progress - Finimize
What Awaits These 4 Biotech Stocks That More Than Doubled in 2025 - Finviz
How Ionis Pharmaceuticals Inc. stock reacts to job market dataJuly 2025 Review & High Accuracy Trade Alerts - ulpravda.ru
Discipline and Rules-Based Execution in IONS Response - news.stocktradersdaily.com
Will Ionis Pharmaceuticals Inc. stock outperform international peers2025 Support & Resistance & Fast Entry High Yield Stock Tips - Улправда
Assenagon Asset Management S.A. Boosts Stock Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
cathie wood’s ARK stock trades highlight ionis pharma sale By Investing.com - Investing.com Canada
cathie wood’s ARK stock trades highlight ionis pharma sale - Investing.com
Dip Buying: How Ionis Pharmaceuticals Inc. stock reacts to job market dataFed Meeting & Weekly Top Performers Watchlists - Улправда
How Ionis Pharmaceuticals Inc. stock compares to industry benchmarksJuly 2025 Sentiment & Reliable Breakout Stock Forecasts - DonanımHaber
Will Ionis Pharmaceuticals Inc. stock gain from government policiesJuly 2025 Snapshot & Safe Swing Trade Setups - DonanımHaber
Can Ionis Pharmaceuticals Inc. stock continue upward trend2025 Growth vs Value & Daily Chart Pattern Signal Reports - DonanımHaber
Is Ionis Pharmaceuticals Inc. stock a safe investment in uncertain marketsForecast Cut & AI Optimized Trading Strategy Guides - Улправда
Ionis Pharmaceuticals Inc (HAM:ISI) Competitors 2025 - GuruFocus
Ionis Pharmaceuticals Inc Stock Operating Data - GuruFocus
Why Ionis Pharmaceuticals Inc. stock is a value investor pickIPO Watch & Proven Capital Preservation Methods - Улправда
Why retail investors favor Ionis Pharmaceuticals Inc. stockWeekly Risk Summary & Safe Entry Point Identification - Улправда
RBC Capital Maintains Ionis Pharmaceuticals (IONS) Outperform Recommendation - Nasdaq
How reliable is Ionis Pharmaceuticals Inc. (ISI) stock dividend growthStock Buyback Updates & Learn the Basics of Investing in 5 Days - Bollywood Helpline
RBC Capital Raises Price Target for Ionis Pharmaceuticals (IONS) to $95 | IONS Stock News - GuruFocus
RBC Raises Price Target on Ionis Pharmaceuticals to $95 From $82, Keeps Outperform Rating - marketscreener.com
Sicart Associates LLC Has $10.75 Million Stock Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis Pharmaceuticals stock price target raised to $95 from $82 at RBC Capital - Investing.com UK
EBITDA per share of Ionis Pharmaceuticals, Inc. – TRADEGATE:ISI - TradingView — Track All Markets
Ionis Pharmaceuticals (IONS): Leerink Partners Raises Price Targ - GuruFocus
Squarepoint Ops LLC Sells 170,978 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
GENESIS Pharma announces a new partnership with Otsuka Pharmaceutical Europe Ltd. for the commercial - pharmiweb.com
Ionis to hold third quarter 2023 financial results webcast - GuruFocus
Ionis Pharmaceuticals, Inc. $IONS Shares Sold by Hudson Bay Capital Management LP - MarketBeat
Marex Group plc Buys New Shares in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Hudson Bay Capital Management LP Has $29.63 Million Holdings in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Levels Update: Can Ionis Pharmaceuticals Inc stock sustain market leadershipJuly 2025 Review & Real-Time Volume Trigger Notifications - moha.gov.vn
Adage Capital Partners GP L.L.C. Raises Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis' Tryngolza Cuts Triglyceride Levels in Late-Stage Study - MSN
B of A Securities Maintains Ionis Pharmaceuticals (IONS) Buy Recommendation - Nasdaq
Ionis Pharmaceuticals (IONS) Price Target Raised by B of A Securities | IONS Stock News - GuruFocus
Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $97.00 - MarketBeat
Angioedema Pipeline 2025: FDA Approvals and Clinical Trials - openPR.com
Ionis Pharmaceuticals, Inc. (IONS) Presents at The 67th American Society of Hematology (ASH) Annual MeetingSlideshow (NASDAQ:IONS) 2025-12-09 - Seeking Alpha
450,254 Shares in Ionis Pharmaceuticals, Inc. $IONS Acquired by Norges Bank - MarketBeat
Polycythemia Vera Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Novartis, Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharm - Barchart.com
Multiple System Atrophy Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma, Brain Neuro - Barchart.com
Can Ionis Pharmaceuticals Stock Hold Up When Markets Turn? - Trefis
Has Ionis Pharmaceuticals Run Too Far After 135% Surge and Bullish DCF Outlook? - Yahoo Finance
Ionis Pharmaceuticals Inc (IONS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.57%
자본화:
|
볼륨(24시간):